NCT04761393

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

Characterizing Mmp12 In Sputum And Its Relationship To Emphysema And Inflammatory Endotypes

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 45 (estimated)
• Sponsor: McMaster University · Academic / Other
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: —

Summary

The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.

Detailed description

Since MMP-12 apparently has a preponderant role in the genesis of emphysema and probably in airspace enlargement, its inhibition may result in an interesting targeting point in view to find specific therapies in obstructive diseases. There is abundant evidence in animal models that shows how MMP-12 blockade inhibits the development of emphysema and airway remodeling. Unfortunately, the results have not been conclusive in human models. In the last years, pulmonary imaging biomarkers that measure airspace enlargement have been developed. In particular, the apparent diffusion coefficient (ADC), quantified by inhaled hyperpolarized gas MRI, reflects alveolar airspace size. ADC provides information consistent with histopathological findings that may be used to estimate lung disease progression and treatment response.

Conditions

• Emphysema

Interventions

Type	Name	Description
PROCEDURE	Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI	Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds

Timeline

• Start date: 2022-11-29
• Primary completion: 2025-01-01
• Completion: 2025-01-01
• First posted: 2021-02-18
• Last updated: 2024-11-20

Locations

1 site across 1 country: Canada